An official website of the United States government
Immunology
Topics
- Allergic Rhinitis (Hay Fever)
- Asthma
- Autoimmune Diseases
- Celiac Disease
- Crohn's Disease
- Food Allergies
- Immune System
- Immunotherapy
- Inflammatory Bowel Disease
- Lupus
- Myasthenia Gravis
- Psoriasis
- Rheumatoid Arthritis
- Sarcoidosis
- Scleroderma
- Sjogren's Disease
- Immunization
- Primary Immunodeficiencies
- Multiple Sclerosis
Retired Program: Accelerating Medicines Partnership® Program for Type 2 Diabetes (AMP T2D) - NIDDK
- Home
- About NIDDK
- Research Areas
- Diabetes
- Accelerating Medicines Partnership® Program for Type 2 Diabetes (AMP T2D)
Related Topics
Vaccine Readiness in People Who Use Substances In Community STI Clinics and Substance Use Intervention or Harm Reduction Programs In Eight Higher HIV Incidence Southeastern Cities
Research is needed to determine prospects for COVID-19 vaccine uptake among people living in higher prevalence communities, hit hard by serial surges, and enacting tenuous policies for COVID-19 mask use, social distancing, and business and social gathering restrictions. Such research is especially crucial for devising strategies to promote vaccine uptake among disenfranchised people of color, who are often limited by disparities due to lower resources and higher mistrust for adopting health care innovations.
Susan Tross, Ph.D
Associate Professor
Accelerating Medicines Partnership® Program for Alzheimer's Disease (AMP® AD)
Accelerating Alzheimer's Research and Drug Development
The Accelerating Medicines Partnership® Program for Alzheimer's Disease (AMP® AD) is a precompetitive partnership among government, industry, and nonprofit organizations to transform the current model for developing new diagnostics and treatments for Alzheimer's disease.
Accelerating Medicines Partnership (AMP)
Scientific Contacts for AMP AD
Laurie Ryan, Ph.D.
Email Laurie Ryan